Intra-Cellular Therapies, Inc.

430 E 29th St Ste 900
New York
New York
10016
United States

Website: http://www.intracellulartherapies.com/

About Intra-Cellular Therapies, Inc.

Intra-Cellular Therapies Inc. is a publicly traded biopharmaceutical company headquartered in New York City. Founded on Nobel-prize winning research, we launched our first commercial product in CNS in 2020 and received approval for an expanded indication in 2021. Currently celebrating our 22nd anniversary, we have a strong pipeline with projects in preclinical development stage through Phase III. We celebrate science, welcome curiosity, expect collaboration and demand integrity and respect in all we do, create and deliver.

“We deliver innovative treatments to improve the lives of individuals suffering from neuropsychiatric, neurologic and other disorders”.

226 articles about Intra-Cellular Therapies, Inc.

Intra-Cellular Therapies, Inc. Announces Multiple Presentations On ITI-007 At The 4th Biennial Schizophrenia International Research Society (SIRS) Conference

4/7/2014
Intra-Cellular Therapies, Inc. Announces Upcoming Presentations At The 4th Biennial Schizophrenia International Research Society Conference

4/3/2014
Intra-Cellular Therapies, Inc. Reports Fourth Quarter And Full-Year 2013 Financial Results

3/26/2014
Intra-Cellular Therapies, Inc. To Announce 2013 Fourth Quarter And Full Year Financial Results And To Host Conference Call On Tuesday, March 25, At 4:30 pm Eastern Time

3/19/2014
Intra-Cellular Therapies, Inc. Announces The Appointment Of Juan Sanchez, M.D., As Vice President Of Corporate Communications And Investor Relations

3/10/2014
Intra-Cellular Therapies, Inc. Announces Initiation Of Phase I/II Clinical Trial For ITI-007 In Healthy Geriatric Subjects And Patients With Dementia, Including Alzheimer's Disease

3/3/2014
Intra-Cellular Therapies, Inc. To Present At The Cowen and Company 34th Annual Healthcare Conference

2/27/2014
Intra-Cellular Therapies, Inc. To Present At Two Upcoming Healthcare Conferences

2/7/2014
Intra-Cellular Therapies, Inc. Announces Completion Of Public Offering And Exercise Of Option To Purchase Additional Shares

2/5/2014
Intra-Cellular Therapies, Inc. Cleared For Quotation On OTCQB

12/20/2013
Intra-Cellular Therapies, Inc. Announces Positive Topline Phase II Clinical Results Of ITI-007 For The Treatment Of Schizophrenia

12/9/2013
Intra-Cellular Therapies, Inc. Announces Closing of $60 Million Private Placement and Completion of Reverse Merger

9/3/2013
Intra-Cellular Therapies, Inc. Appoints Professor Sir Michael Rawlins to its Board of Directors

5/14/2013
Intra-Cellular Therapies, Inc. Announces Completion of Phase I Single Rising Dose Trial of First-in-Class Selective Phosphodiesterase 1 (PDE1) Inhibitor and Reports Top-line Safety and Pharmacokinetic Findings

2/19/2013
Intra-Cellular Therapies, Inc. and Takeda Pharmaceutical Co. Ltd. Enter into Worldwide Collaboration to Develop and Commercialize Compounds for Schizophrenia in Deal Worth $750 Million Potentially

3/3/2011
Intra-Cellular Therapies, Inc. Announces Positive Results with ITI-002 in Pre-Clinical Models of Parkinson's Disease

10/1/2010
Intra-Cellular Therapies, Inc. Announces the Successful Completion of a Phase Ib/II Study of ITI-007 in Patients with Schizophrenia

7/29/2010
Intra-Cellular Therapies, Inc. Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia

3/10/2009
Intra-Cellular Therapies, Inc. Announces Successful Outcome of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia

1/13/2009
Intra-Cellular Therapies, Inc. Announces the Discovery of Potent Antidepressant Activity in ITI-007/ITI-722

4/9/2008

First
Previous
11
12
Next
Last